News Sentiment

CUE sentiment intelligence

Cue Biopharma news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 36.78 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

88/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+30.1% over one week, +49.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Form 4 Cue Biopharma For: 15 July By Investing.com

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 88/100 classification
One-week reaction 30.1% Price confirming higher
Trend fit Trend active 49.9% over four weeks
Fair value -4.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 46
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
TradingView 10
GlobeNewswire 7
Market source 6
Investing.com 3
Moomoo 3
Investing.com Canada 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 47
Earnings 13
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
GlobeNewswire Direct company coverage

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

Cue Biopharma (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. Dr. Borie brings over two decades of experience in immunology and clinical development to the company and will report to President and CEO Shao-Lee L

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 15:40
Source
GlobeNewswire
Investing.com Direct company coverage

Cue Biopharma names Dominic Borie as chief medical officer

Cue Biopharma has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. This strategic move coincides with the company's advancement of therapies for immune-mediated diseases, including upcoming Phase 2 data for CUE-221 and the initiat

Tone
Positive 66/100
Event
Market update
Published
13 Jul 2026 13:09
Source
Investing.com
TradingView Direct company coverage

ETFs Investing in Cue Biopharma, Inc. Stocks

This article lists Exchange Traded Funds (ETFs) that hold stocks of Cue Biopharma, Inc. (CUE). It highlights one such fund, the iShares Microcap ETF (IWC), providing details like its market value, weight of CUE stock, expense ratio, and performance. The information aims to help i

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 13:09
Source
TradingView
Stock Titan Direct company coverage

Immunology veteran Dominic Borie to steer Cue Biopharma’s drug pipeline

Cue Biopharma (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as its Chief Medical Officer and Head of Research & Development. This strategic hire aligns with the company's advancement of its clinical programs, including an expected Phase 2 CSU data readout for CUE-221 by

Tone
Positive 76/100
Event
Market update
Published
13 Jul 2026 12:09
Source
Stock Titan
RTTNews Direct company coverage

Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH

Several biotech stocks, including American Well Corporation (AMWL), Cue Biopharma Inc. (CUE), ImmuCell Corporation (ICCC), Scholar Rock Holding Corp. (SRRK), and Faeth Therapeutics Inc. (FTH), reached 52-week highs on July 10, 2026. These highs were driven by positive development

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 11:09
Source
RTTNews
TradingView Direct company coverage

Price to earnings forward of Cue Biopharma, Inc. – MUN:1UC0

This article provides access to financial data for Cue Biopharma, Inc. (1UC0) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data page from TradingView, offering an overview of the company's financial perform

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 19:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cue Biopharma, Inc. – MUN:1UC0

This article displays the "Enterprise value to revenue forward" metric for Cue Biopharma, Inc. (MUN:1UC0) on the Munich Stock Exchange, as provided by TradingView. It shows that the market is currently closed with no trades recorded for this particular metric. The content highlig

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 08:39
Source
TradingView
Stock Titan Direct company coverage

Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant

Meehan Viola Mong, a director at Cue Biopharma, received a grant of 21,800 restricted stock units (RSUs) of Common Stock. These RSUs were granted at $0.00 per share and will vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, contingent on continued

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 15:40
Source
Stock Titan
Stock Titan Direct company coverage

Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs

Cue Biopharma (Nasdaq: CUE) has successfully completed a private placement, raising approximately $50.0 million from accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments. This financing involved issuing common stock and pre-funded warran

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 02:11
Source
Stock Titan
Stock Titan Direct company coverage

Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief

Cue Biopharma, Inc. granted its Chief Legal Compliance Officer and Corporate Secretary, Sumita Ray, a total of 109,178 shares in equity awards. This package includes 54,589 restricted stock units (RSUs) vesting quarterly over 48 months and 54,589 performance stock units (PSUs) wi

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package

Cue Biopharma's CEO, Shao-Lee Lin, was granted equity awards totaling 327,537 shares of common stock on July 9, 2026, comprising restricted stock units (RSUs) and performance stock units (PSUs). The RSUs will vest over 48 months, while the PSUs are tied to specific stock price ta

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award

Cue Biopharma director Sarraf Pasha was granted 21,800 restricted stock units (RSUs), which will vest in three equal installments on July 9, 2027, 2028, and 2029, dependent on his continued service. Following this award and after a 1-for-30 reverse stock split on April 22, 2026,

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Cue Biopharma (CUE) awards 21,800 restricted stock units to board director

Cue Biopharma, Inc. (CUE) awarded 21,800 restricted stock units (RSUs) to board director Daniel A. Camardo. These RSUs will vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, contingent on his continued service to the company. Following this transac

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:09
Source
Stock Titan
TradingView Direct company coverage

Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle

Cue Biopharma announced a private placement aiming to raise approximately $50 million. The financing, expected to close on July 13, 2026, involves investors like Cormorant Asset Management and Columbia Threadneedle Investments purchasing common shares and pre-funded warrants. The

Tone
Positive 72/100
Event
Market update
Published
10 Jul 2026 21:09
Source
TradingView
Moomoo Direct company coverage

Cue Biopharma Shares Rise on $50 Million Private Placement Pricing

Cue Biopharma announced the pricing of a $50 million private placement of its common stock and pre-funded warrants. The offering included existing as well as new investors. Proceeds from the placement are intended to fund the company's CUE-100 series clinical trials, expand the C

Tone
Positive 70/100
Event
Market update
Published
10 Jul 2026 17:10
Source
Moomoo
Moomoo Direct company coverage

Cue Biopharma Announces $50 Million Private Placement

Cue Biopharma has announced a private placement of its common stock and pre-funded warrants, aiming to raise approximately $50 million. The financing includes participation from existing investors, new healthcare-focused funds, and members of the company's management and board. P

Tone
Positive 71/100
Event
Market update
Published
10 Jul 2026 09:09
Source
Moomoo
GuruFocus Direct company coverage

Cue Biopharma (CUE) Secures $50M in Private Placement Financing

Cue Biopharma (CUE) has finalized a securities purchase agreement to raise approximately $50.0 million through an oversubscribed private placement with institutional investors. The company will issue 1.42 million shares at $33.21 each and pre-funded warrants. This funding aims to

Tone
Positive 71/100
Event
Market update
Published
10 Jul 2026 08:40
Source
GuruFocus
Investing.com Direct company coverage

Cue Biopharma raises $50M in private placement

Cue Biopharma (NASDAQ:CUE) announced a private placement to raise approximately $50 million by issuing common stock and pre-funded warrants to accredited investors. Cormorant Asset Management led the placement, with funds intended for clinical development and general corporate pu

Tone
Positive 66/100
Event
Market update
Published
10 Jul 2026 03:40
Source
Investing.com
Stock Titan Direct company coverage

Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs

Cue Biopharma announced a $50 million private placement, including common shares and pre-funded warrants, led by Cormorant Asset Management and Columbia Threadneedle Investments. The company plans to use the proceeds to fund clinical development and corporate purposes, specifical

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 02:40
Source
Stock Titan
Quiver Quantitative Direct company coverage

Cue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset Management

Cue Biopharma has secured $50 million through a private placement of common stock and pre-funded warrants, led by Cormorant Asset Management and including Columbia Threadneedle Investments. The funds will support clinical development and general corporate purposes, with the trans

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 01:50
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Cue Biopharma Announces $50.0 Million Private Placement

Cue Biopharma, Inc. announced a private placement of common stock and pre-funded warrants valued at approximately $50.0 million. The placement was led by Cormorant Asset Management and includes Columbia Threadneedle Investments with the proceeds intended for clinical development

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 21:40
Source
GlobeNewswire